OC-01 (varenicline) nasal spray, 1.2 mg/mL for Neurotrophic Keratopathy

"Currently, 26 trials involving OC-01 (varenicline) nasal spray, 1.2 mg/mL are ongoing with 4 of those studies in their final phase. The primary location for these tests is Charleston, South carolina but there are 69 other sites across the country running trial programs as well."

"According to clinicaltrials.gov, this particular research endeavor is not currently recruiting patients; it was initially posted on June 17th 2021 and last modified on November 15th 2022. However, 28 other trials are presently accepting participants at this time."

"Unfortunately, the recruitment process for this trial has concluded. It was first posted on June 17th 2021 and subsequently edited on November 15th 2022. For those looking to participate in study trials, there are currently two clinical studies recruiting participants with neurotrophic keratopathy and 26 involving OC-01 (varenicline) nasal spray, 1.2 mg/mL that have open recruitment periods."

"Currently, 32 sites are enlisting participants for the trial. These locations range from Aurora to Los Angeles and Dothan - selecting a site close by could help reduce travel complications if you choose to join in on this study."

"This 8-week long trial will primarily measure changes in corneal fluorescein staining. In addition, the secondary endpoints of this research include evaluating visual acuity at week 8 (Secondary Endpoint #1), calculating the percentage of subjects that progress to Stage 2 Persistent Epithelial Defect (PED) NK by Week 8 (Secondary Endpoint #2), and gauging improvements in corneal sensitivity at week 8 (Secondary Endpoint #3)."

"Due to limited data demonstrating efficacy, the safety of OC-01 (varenicline) nasal spray, 1.2 mg/mL was estimated as a 2 on our team's rating scale."